If you’ve had a standard cholesterol panel, you’ve seen the same four numbers: total cholesterol, LDL, HDL, triglycerides. Maybe everything looked fine. Maybe LDL was slightly elevated, and you left with a conversation about diet or statins. Either way, the panel did what it was designed to do.
But here is something that rarely makes it into that conversation: a significant proportion of people who experience heart attacks had LDL levels that would have been considered acceptable beforehand. The panel didn’t fail — it answered the question it was built to answer. The problem is that the question was incomplete.
Ceramides sit in what that question left out.
What’s moving through your bloodstream — and why direction matters
Before getting to ceramides, it helps to understand the traffic system they travel through — because direction is everything in lipid biology.
LDL — low-density lipoprotein — moves cholesterol outward, from the liver to peripheral tissues. When LDL deposits cholesterol in arterial walls, it contributes to plaque. HDL — high-density lipoprotein — runs the opposite route, pulling cholesterol from peripheral tissues back to the liver for processing. This is why LDL and HDL carry such different cardiovascular implications despite both being cholesterol carriers: not just quantity, but direction.
Ceramides travel on these same lipoproteins. They are synthesized primarily in the liver and exported into circulation packaged within LDL and VLDL particles — the outward-moving pool, the same particles implicated in atherogenesis.¹ This is not a minor detail. It means that what you measure in plasma reflects, in part, what the liver is producing and releasing outward — which in turn reflects the metabolic and inflammatory signals the liver is receiving.
What ceramides are — and what drives them up
Ceramides are a family of lipid molecules belonging to a broader class called sphingolipids. Under normal, unstressed conditions, ceramide is a minor component of cell membranes — it exists there in small quantities as part of the structural architecture, but it isn’t the dominant player.¹ The picture changes when cells are under stress.
The main manufacturing pathway works like this: your body combines a saturated fatty acid — most commonly palmitate, the dominant saturated fat in the Western diet — with an amino acid called serine. The enzyme driving this reaction is serine palmitoyl transferase, the rate-limiting step in ceramide biosynthesis.¹ A second, faster route involves enzymes called sphingomyelinases, which are activated by inflammatory signals and cellular stress. These enzymes cleave sphingomyelin — a far more abundant membrane lipid — releasing ceramide locally and rapidly.¹ So you end up with two sources feeding the same pool: the slow, substrate-driven de novo synthesis route, and the fast, stress-responsive hydrolysis route.
This dual origin matters for interpretation. Chronically elevated ceramides can reflect sustained dietary saturated fat load, ongoing inflammatory signaling, or both simultaneously. The connection runs deeper than diet alone: in animal models, saturated fatty acids have been shown to activate TLR4, an innate immune receptor, which in turn upregulates genes driving ceramide biosynthesis — providing a potential molecular link between diet, inflammation, and ceramide biosynthesis.² And because serine palmitoyl transferase is the rate-limiting enzyme, genetic variation in the genes encoding it also influences where your baseline ceramide levels sit — independent of diet or lifestyle.³ More on that in a moment.
The chain length detail that changes everything
Not all ceramides behave the same. The notation used in the literature describes each species by two numbers: the chain length of the attached fatty acid, and the number of double bonds indicating saturation. C16:0 means a 16-carbon chain, no double bonds — fully saturated. C24:1 means a 24-carbon chain, one double bond — monounsaturated.
This matters because chain length and saturation determine biological behavior. C16:0, the shorter saturated species, is the biologically aggressive one: it activates inflammatory pathways, is strongly associated with the promotion of endothelial dysfunction, and interferes with insulin signaling. ¹ C24:0, the longer species, appears to have more protective or metabolically neutral effects at the cellular level. ⁴ They are not the same molecule, with a slightly different tail. They have different signaling properties, different tissue distributions, and in the cardiovascular literature, opposite associations with outcome.
This is why the research converged on ratios rather than absolute levels. The ratio of C16:0 to C24:0 captures the balance between the biologically stressful and the more protective species. It is more informative than either concentration alone, partly because it normalizes for the substantial between-person variation in overall ceramide production capacity that comes from genetics, body composition, and hepatic metabolism.⁴ Two people can have identical C16:0 levels but very different C16:0/C24:0 ratios — and very different biological pictures.
A brief note on absolute quantification: plasma ceramide measurements report concentrations, typically in nanomoles per litre, that vary considerably across individuals and laboratories. Standardization of analytical methods across sites remains an active area of development in the field — which is part of why ratios, being internally normalized, have proven more robust across independent cohorts than absolute concentrations of individual species.¹
Genetics: the baseline you didn’t choose
Before the diet, before the inflammation, before any lifestyle factor enters the picture — some of the variation in your ceramide levels is simply inherited.
A genome-wide association study of nearly 1,000 individuals from 196 British families found that ceramide species are significantly heritable, with heritability estimates ranging from 36% to 62% depending on the species.³ The strongest genetic signal mapped to the SPTLC3 locus — a gene encoding a subunit of serine palmitoyl transferase, the same rate-limiting enzyme in ceramide biosynthesis. Variants in this gene associated with a range of ceramide species at genome-wide significance.
This has a direct implication for interpretation: two individuals eating identical diets can have meaningfully different ceramide profiles, not because of anything they’re doing differently, but because of inherited differences in how efficiently their cells produce ceramide. It doesn’t make the measurement less useful — it makes context more important.
What the evidence actually shows
The prospective human data here is notable. Not because one study found an association, but because the association has been independently replicated — which in biomarker science is the critical threshold.
A 2016 study published in the European Heart Journal followed patients with stable coronary artery disease and acute coronary syndromes across three independent cohorts — Finnish, Swiss, and Norwegian populations. Ceramide ratios, particularly Cer(d18:1/16:0)/Cer(d18:1/24:0), predicted cardiovascular death independently of LDL-cholesterol, HDL, and C-reactive protein.⁵ The adjusted odds ratios per standard deviation increase in the ratio [adjusted for established cardiovascular risk factors including age, sex, smoking, blood pressure, diabetes, and LDL-cholesterol, as used in the standard Framingham risk score — a widely used tool to estimate 10-year heart disease risk] reached 4.49 in the discovery cohort, with consistent replication in the Swiss and Norwegian validation cohorts at 1.64 and 1.77 respectively.⁵ Adding ceramide ratios to established clinical risk scores meaningfully improved the ability to correctly reclassify patients by risk.
That same year, the FINRISK 2002 cohort extended the finding into a different population: 8,101 apparently healthy Finns, followed from 2002 until 2014. Cer(d18:1/18:0) had the strongest association with incident major adverse cardiovascular events, with an adjusted hazard ratio of 1.21 after Framingham risk factor adjustment, and improved net reclassification by 7.5%.⁶ This matters because FINRISK was a population-based survey — not patients with existing disease.
The community-based evidence continued to build. A study using Framingham Heart Study and Study of Health in Pomerania participants — 2,642 and 3,134 individuals respectively, without prior cardiovascular disease at baseline — found that the C24:0/C16:0 ceramide ratio was inversely associated with incident coronary heart disease (hazard ratio 0.79 per standard deviation, p<0.0001), heart failure, and all-cause mortality across both cohorts in meta-analysis.⁷ The direction of the ratio here is intuitive: higher C24:0 relative to C16:0 — more of the protective species relative to the aggressive one — associated with lower risk. Replicated in two independent community populations, over follow-up periods extending to more than eight years.
A 2020 study in Atherosclerosis followed 1,704 coronary artery disease patients over a median of 9.3 years. Each standard deviation increase in the C16:0/C24:0 ratio was associated with a 27% increase in cardiovascular mortality risk and a 29% increase in all-cause mortality after multivariable adjustment.⁸ A 2023 multicenter prospective study of acute coronary syndrome patients found that ceramide ratios, combined with standard clinical risk scores, improved predictive accuracy beyond either approach alone.⁹
The picture that emerges across these studies: a consistent, replicated signal, across CAD patients and apparently healthy community populations, across Finnish, Norwegian, Swiss, German, and American cohorts.
What this can and cannot tell you
Here is where interpretation requires care — because this is exactly the functional readout versus predictive claim distinction that ran through the previous series.
The ceramide data is now strongest not just in established CAD populations but also in general community populations — two independent datasets (FINRISK and Framingham/SHIP) support a signal in people without prior cardiovascular disease. What this measurement can honestly support: ceramide ratios reflect the balance between biologically stressful and protective sphingolipid states, and add risk stratification information that LDL-cholesterol cannot provide, both in patients with established cardiovascular disease and increasingly in the general population.
What this measurement does not support: a ceramide result cannot tell you when an adverse event might occur, whether one will occur at all, or whether a specific intervention will shift your ratio and change your trajectory. The intervention question is biologically plausible — if saturated fat provides the substrate for de novo ceramide synthesis, and inflammatory signaling through TLR4 further activates that pathway, then reducing chronic saturated fat intake and systemic inflammation addresses upstream inputs directly. Human evidence supports this direction: a nested study within the PREDIMED randomized trial found that a higher ceramide score was associated with a 2.18-fold increase in incident cardiovascular events, and that Mediterranean dietary intervention attenuated that elevated risk in high-ceramide participants.¹⁰ That is not a ceramide-targeted intervention, but it is the closest the field currently has to randomized evidence that dietary pattern modifies the ceramide-risk relationship in humans. Still, “dietary pattern associated with lower ceramide risk” and “ceramide reduction demonstrated to change outcomes” remain two different evidence thresholds.
The open question that matters most: as the community population data matures and diversifies across ethnicities and ancestries, do the effect sizes hold? The current evidence base is predominantly European. That is a real limitation, and the field is actively building the multi-ancestry data to address it.
Why this matters beyond the result
The ceramide story is a useful case study in what a credible functional biomarker actually looks like: a clear biological mechanism, a measurement that distinguishes between species with meaningfully different properties, evidence from independent prospective cohorts across multiple countries and populations, and an explicit, honest interpretation boundary.
Your standard cholesterol panel is a powerful tool for what it was built to do. Ceramide ratios are not a replacement, rather an additional layer of information, with clearly defined conditions under which that layer is most informative.
The number on your panel is real. Whether it’s the right question for where you sit biologically — that’s what the biography is for.
Scientific note: This article cites peer-reviewed evidence, clinical guidelines, and reported professional consensus throughout. Sources are independently verifiable and listed below. Claims about individual tests are scoped to the published literature cited and do not constitute medical advice.
José Carlos Bozelli Jr., PhD, is a lipid biochemist, omics data scientist, and scientific writer. He advises biotech, CRO, and health-tech teams on lipidomics, large-scale omics data pipelines, and biomarker science, and translates complex molecular data into decisions for scientists, clinicians, and builders.
The content of this article is for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before making decisions based on biomarker results.
References
Choi RH, et al. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021;18(10):701–711. DOI: 10.1038/s41569-021-00536-7
Holland WL, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid–induced ceramide biosynthesis in mice. J Clin Invest. 2011;121(5):1858–1870. DOI: 10.1172/JCI43378
McGurk KA, et al. Heritability and family-based GWAS analyses of the N-acyl ethanolamine and ceramide plasma lipidome. Hum Mol Genet. 2021;30(6):500–513. DOI: 10.1093/hmg/ddab002
Park LK, et al. Links between ceramides and cardiac function. Curr Opin Lipidol. 2022;33(1):47–56. DOI: 10.1097/MOL.0000000000000802
Laaksonen R, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967–76. DOI: 10.1093/eurheartj/ehw148
Havulinna AS, et al. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. Arterioscler Thromb Vasc Biol. 2016;36(12):2424–30. DOI: 10.1161/ATVBAHA.116.307497
Peterson LR, et al. Ceramide remodeling and risk of cardiovascular events and mortality. J Am Heart Assoc. 2018;7(24):e007931. DOI: 10.1161/JAHA.118.007931
Li Q, et al. Associations between plasma ceramides and mortality in patients with coronary artery disease. Atherosclerosis. 2020;314:77–83. DOI: 10.1016/j.atherosclerosis.2020.09.004
Li F, et al. Association between plasma ceramides and one-year mortality in patients with acute coronary syndrome: insight from the PEACP study. Clin Interv Aging. 2023;18:571–584. DOI: 10.2147/CIA.S402253
Wang DD, et al. Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED trial. Circulation. 2017;135(21):2028–2040. DOI: 10.1161/CIRCULATIONAHA.116.024261